Key outcomes:

• Establishment of spin-off company, Celosia Therapeutics ($2 million seed funding followed by series A of $16.5 million)
• Commenced Phase 1b KOANEWA trial evaluating CTx1000 in March 2026
• Fight MND Foundation Impact Grant, $250,000
• Fight MND Foundation Drug Development Grant, $1,000,000
• NHMRC Ideas Grant, $794,115
• Prof. Chung was awarded the 2023 NHMRC Marshall and Warren Innovation Award

Read more